Brandon Vu

Brandon Vu

Auto-generated profile, based on publicly available information

Brandon Vu

Department of Surgery, Riverside University Health System, Moreno Valley, California

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
WOW. Quinn O'Neill
W. Quinn O'Neill
JWJay Wasman
Jay Wasman
JTJason Thuener
Jason Thuener
KCKate Chatfield-Reed
Kate Chatfield-Reed
LLLizabeth Lukesic
Lizabeth Lukesic
QPQuintin Pan
Quintin Pan
Human papilloma virus–positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), diagnosed with p16 immunohistochemistry, is associated with favorable prognosis; however, this connection was established using European American (EA)–skewed populations. The impact of p16/human papillomavirus status on outcomes in African American (AA) OPSCC patients remains to be settled. In this study, we determine the association between cancer disparity and p16 status in an OPSCC cohort controlling for time to treatment initiation (TTI), a surrogate for medical care access. We analyzed data from all patients diagnosed with OPSCC (N = 440) between 2010 and 2017, who received treatment at our academic medical center. Associations between age, disease stage, sex, p16 status, race, TTI, and overall survival (OS) were investigated. TTI was similar between AA and EA OPSCC patients in our p16+ (P = .291) or p16− (P = .715) cohorts. Among p16+ OPSCC patients, the median OS was > 8.65 years for EA patients compared with 5.038 years (95% CI, 2.019 to 5.30; P = .003, log-rank) for AA patients. For p16− patients, the median OS was 5.74 years (95% CI, 3.32 to 6.99) for EA patients and 1.85 years (95% CI, 0.978 to 4.50; P = .03, log-rank) for AA patients. Multivariate Cox regression analysis showed that race was an independent prognostic biomarker and the most impactful co-variate for OS (hazard ratio, 0.40; 95% CI, 0.00 to 0.69; P = .001). Our work showed that AAs with p16+ OPSCC have surprisingly poor clinical outcomes and are thus poor candidates for treatment de-escalation regimens. Caution should be exercised when extending clinical guidelines based on EA-majority studies to non-EA populations.

15 April 2022 in Oral Oncology
Verified
Journal Article
Closed access
RMR. Grant Muller
R. Grant Muller
CHChelsea S. Hamill
Chelsea S. Hamill
BVBrandon Vu
Brandon Vu
JTJason Thuener
Jason Thuener
JWJay Wasman
Jay Wasman
WOWQ O'Neill
WQ O'Neill

27 July 2023 in Journal of Surgical Research
Verified
Journal Article
Closed access
TSTrevor Silva
Trevor Silva
MTMorvarid Tavassoli
Morvarid Tavassoli
ELEsther Lee
Esther Lee
LNLan-Anh Annie Nguyen
Lan-Anh Annie Nguyen
BVBrandon Vu
Brandon Vu
SLSharon Lum
Sharon Lum